214 related articles for article (PubMed ID: 11078490)
1. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer.
Baekelandt M; Holm R; Nesland JM; Tropé CG; Kristensen GB
J Clin Oncol; 2000 Nov; 18(22):3775-81. PubMed ID: 11078490
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer.
Marx D; Binder C; Meden H; Lenthe T; Ziemek T; Hiddemann T; Kuhn W; Schauer A
Anticancer Res; 1997; 17(3C):2233-40. PubMed ID: 9216694
[TBL] [Abstract][Full Text] [Related]
4. Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
Shigemasa K; Katoh O; Shiroyama Y; Mihara S; Mukai K; Nagai N; Ohama K
Jpn J Cancer Res; 2002 May; 93(5):542-50. PubMed ID: 12036450
[TBL] [Abstract][Full Text] [Related]
5. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
[TBL] [Abstract][Full Text] [Related]
6. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
8. p53 and related proteins in epithelial ovarian cancer.
Sengupta PS; McGown AT; Bajaj V; Blackhall F; Swindell R; Bromley M; Shanks JH; Ward T; Buckley CH; Reynolds K; Slade RJ; Jayson GC
Eur J Cancer; 2000 Dec; 36(18):2317-28. PubMed ID: 11094305
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy.
Wootipoom V; Lekhyananda N; Phungrassami T; Boonyaphiphat P; Thongsuksai P
Gynecol Oncol; 2004 Sep; 94(3):636-42. PubMed ID: 15350352
[TBL] [Abstract][Full Text] [Related]
10. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
[TBL] [Abstract][Full Text] [Related]
11. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.
Nehls O; Okech T; Hsieh CJ; Enzinger T; Sarbia M; Borchard F; Gruenagel HH; Gaco V; Hass HG; Arkenau HT; Hartmann JT; Porschen R; Gregor M; Klump B
Br J Cancer; 2007 May; 96(9):1409-18. PubMed ID: 17426704
[TBL] [Abstract][Full Text] [Related]
12. P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Seidal T
Int J Gynecol Cancer; 2001; 11(2):147-58. PubMed ID: 11328414
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.
Kupryjańczyk J; Szymańska T; Madry R; Timorek A; Stelmachów J; Karpińska G; Rembiszewska A; Ziółkowska I; Kraszewska E; Debniak J; Emerich J; Ułańska M; Płuzańska A; Jedryka M; Goluda M; Chudecka-Głaz A; Rzepka-Górska I; Klimek M; Urbański K; Breborowicz J; Zieliński J; Markowska J
Br J Cancer; 2003 Mar; 88(6):848-54. PubMed ID: 12644821
[TBL] [Abstract][Full Text] [Related]
14. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities.
Sarbia M; Stahl M; Fink U; Willers R; Seeber S; Gabbert HE
Clin Cancer Res; 1998 Dec; 4(12):2991-7. PubMed ID: 9865911
[TBL] [Abstract][Full Text] [Related]
15. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S; N'Diaye M; Blanc-Fournier C; Dugué AE; Clarisse B; Dutoit S; Giffard F; Abeilard E; Briand M; Labiche A; Grellard JM; Crouet H; Martin S; Joly F; Poulain L
Int J Cancer; 2015 Mar; 136(5):E340-50. PubMed ID: 25066666
[TBL] [Abstract][Full Text] [Related]
16. TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.
Ziółkowska-Seta I; Madry R; Kraszewska E; Szymańska T; Timorek A; Rembiszewska A; Kupryjańczyk J
Gynecol Oncol; 2009 Jan; 112(1):179-84. PubMed ID: 18937971
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas.
Kato K; Kawashiri S; Yoshizawa K; Kitahara H; Yamamoto E
J Oral Pathol Med; 2008 Jul; 37(6):364-71. PubMed ID: 18410312
[TBL] [Abstract][Full Text] [Related]
19. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
[TBL] [Abstract][Full Text] [Related]
20. The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment.
Skírnisdóttir I; Seidal T
Oncol Rep; 2012 Mar; 27(3):741-7. PubMed ID: 22159712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
